VERTEX PHARMACEUTICALS INC / MA Income (Loss) from Continuing Operations before Income Taxes, Domestic
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $2.82 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $2.82B.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$1.37B, a 144.34% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $3.09B, a 5.16% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $3.26B, a 60.39% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.82B 10-K · filed 2026-02-13 | |
| 2024-12-31 | -$1.37B 10-K · filed 2026-02-13 | |
| 2023-12-31 | $3.09B 10-K · filed 2026-02-13 | |
| 2022-12-31 | $3.26B 10-K · filed 2025-02-13 | |
| 2021-12-31 | $2.03B 10-K · filed 2024-02-15 | |
| 2020-12-31 | $2.89B 10-K · filed 2023-02-10 | $2.89B 10-K · filed 2021-02-11 |
| 2019-12-31 | $1.26B 10-K · filed 2022-02-09 | $1.26B 10-K · filed 2020-02-13 |
| 2018-12-31 | $812.09M 10-K · filed 2021-02-11 | |
| 2017-12-31 | $330.34M 10-K · filed 2020-02-13 | |
| 2016-12-31 | -$147.86M 10-K · filed 2019-02-13 | |
| 2015-12-31 | -$272.33M 10-K · filed 2018-02-15 | |
| 2014-12-31 | -$645.47M 10-K · filed 2017-02-23 | |
| 2013-12-31 | -$10.64M 10-K · filed 2016-02-16 | -$390.01M 10-K · filed 2014-02-11 |
| 2012-12-31 | $231.54M 10-K · filed 2015-02-13 | $256.82M 10-K · filed 2013-03-01 |
| 2011-12-31 | $343.51M 10-K · filed 2014-02-11 | |
| 2010-12-31 | -$719.86M 10-K · filed 2013-03-01 | |
| 2009-12-31 | -$621.46M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |